Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response

Oncotarget

Volumn 7, Issue 36, 2016, Pages 57581-57592

  Jacobs, Ruschca ^a   Malherbe, Stephanus ^a   Loxton, Andre G ^a   Stanley, Kim ^a   van der Spuy, Gian ^a   Walzl, Gerhard ^a   Chegou, Novel N ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Acute phase proteins; Biomarker; Diagnosis; Immune response; Immunity; Immunology and microbiology section; Neural cell adhesion molecule (NCAM); Tuberculosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CXCL9 CHEMOKINE; FERRITIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NERVE CELL ADHESION MOLECULE; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; TISSUE PLASMINOGEN ACTIVATOR; GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TREATMENT RESPONSE; TUBERCULOSIS; BLOOD; COMPLICATION; IMMUNOLOGICAL PROCEDURES; LUNG TUBERCULOSIS; METABOLISM; MIDDLE AGED; POINT OF CARE SYSTEM; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SOUTH AFRICA;

ADULT; BIOMARKERS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC TESTS; INTERFERON-GAMMA; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84988372486     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11420     Document Type: Article

References (46)

1. WHO, Global Tuberculosis Report, 2015.
2. Desikan P: Sputum smear microscopy in tuberculosis: Is it still relevant? Indian J Med Res 2013, 137:442-444.
3. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR: Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010, 10:387-394.
4. Zeka AN, Tasbakan S, Cavusoglu C: Evaluation of the GeneXpert MTB/RIF Assay for Rapid Diagnosis of Tuberculosis and Detection of Rifampin Resistance in Pulmonary and Extrapulmonary Specimens. J Clin Microbiol 2011, 49:4138-4141.
5. Miotto P, Bigoni S, Migliori GB, Matteelli A, Cirillo DM: Early tuberculosis treatment monitoring by Xpert(R) MTB/ RIF. Eur Respir J 2012, 39:1269-1271.
6. Denkinger CM, Pai M, Patel M, Menzies D: Gamma Interferon Release Assay for Monitoring of Treatment Response for Active Tuberculosis: an Explosion in the Spaghetti Factory. J Clin Microbiol 2013, 51:607-610.
7. Higuchi K, Harada N, Mori T: Interferon-γ responses after isoniazid chemotherapy for latent tuberculosis. Respirology 2008, 13:468-472.
8. Jacobs R, Tshehla E, Malherbe S, Kriel M, Loxton AG, Stanley K, van der Spuy G, Walzl G, Chegou NN: Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment. Cytokine 2016, 81:50-56.
9. Phalane KG, Kriel M, Loxton AG, Menezes A, Stanley K, van der Spuy GD, Walzl G, Chegou NN: Differential Expression of Host Biomarkers in Saliva and Serum Samples from Individuals with Suspected Pulmonary Tuberculosis. Mediators Inflamm 2013, 2013:1-10.
10. Chegou, N, Walzl.G, Mihret,A: Method for diagnosing Tuberculosis. International Patent Application No PCT/ IB2015/051435. https://patentscope.wipo.int/search/en/ detail.jsf?docId = WO2015128830.
11. Chegou NN, Sutherland JS, Malherbe S, Crampin AC, Corstjens PLAM, Geluk A, Mayanja-Kizza H, Loxton AG, van der Spuy G, Stanley K, Kotzé LA, van der Vyver M, Rosenkrands I, Kidd M, van Helden PD, Dockrell HM, Ottenhoff THM, Kaufmann SHE, Walzl G: Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB. Thorax 2016, 71:785-794.
12. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A: Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011, 11:343-354.
13. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA: Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment. PLoS ONE 2013, 8:e61002.
14. Fluss R, Faraggi D, Reiser B: Estimation of the Youden Index and its Associated Cutoff Point. Biom J 2005, 47:458-472.
15. General Discriminant Analysis-Statistics Textbook [http:// documents.software.dell.com/Statistics/Textbook/General-Discriminant-Analysis] Last Accessed: 31 May 2016.
16. Chen T, Li H, Lin J, Guo H, Wang W, Chen L, Zhang X, Wang Y, Chen Y, Liao Q, others: Profiling the Human Immune Response to Mycobacterium Tuberculosis by Humane Cytokine Array. Tuberculosis 2016, 97: 108-117.
17. Chegou NN, Heyckendorf J, Walzl G, Lange C, Ruhwald M: Beyond the IFN-γ horizon: Biomarkers for immunodiagnosis of infection with M. tuberculosis. Eur Respir J 2014, 43: 1472-1486.
18. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ: Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci 2005, 6B:1045-1056.
19. Shaikh MK, Samo JA, Devrajani BR, Shah SZA, Shaikh S, Shaikh I: C-reactive protein in patients with pulmonary tuberculosis. World Appl Sci J 2012, 17:140-144.
20. Rao S, Bernhardt V: Serum C-reactive protein in pulmonary tuberculosis: correlation with bacteriological load and extent of disease. Infect Dis Clin Pract 2009, 17:314-316.
21. Noursadeghi M, Bickerstaff MC, Gallimore JR, Herbert J, Cohen J, Pepys MB: Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc Natl Acad Sci 2000, 97:14584-14589.
22. Kotru M, Rusia U, Sikka M, Chaturvedi S, Jain AK: Evaluation of serum ferritin in screening for iron deficiency in tuberculosis. Ann Hematol 2004, 83:95-100.
23. Opolot JO, Theron AJ, Anderson R, Feldman C: Acute phase proteins and stress hormone responses in patients with newly diagnosed active pulmonary tuberculosis. Lung 2015, 193:13-18.
24. Radovic M, Pejcic T, Stankovic I, Ristic L, Rancic M, Ciric Z: Acute-Phase Inflammatory Response in Patients with Pulmonary Tuberculosis. Acta Fac Medicae Naissensis 2014, 31:183-191.
25. Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, Garcia-Zepeda EA, Hamid Q, Luster AD: The T cellspecific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999, 162:3549-3558.
26. Ferrara G, Bleck B, Richeldi L, Reibman J, Fabbri LM, Rom WN, Condos R: Mycobacterium tuberculosis Induces CCL18 Expression in Human Macrophages: CCL18 in Tuberculosis Infection. Scand J Immunol 2008, 68:668-674.
27. Haque NS, Fallon JT, Taubman MB, Harpel PC: The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein (a)-stimulated endothelial cell conditioned medium. Blood 2001, 97:39-45.
28. Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho S-N, Kim SK, Chang J, Kang YA: Efficacy of inducible protein 10, as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 2012, 16:e855-e859.
29. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD: CXCR3 Internalization Following T Cell-Endothelial Cell Contact: Preferential Role of IFN-Inducible T Cell Chemoattractant (CXCL11). J Immunol 2001, 167:7084-7093.
30. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee S-J: Characterization of growthdifferentiation factor 15, a transforming growth factor β superfamily member induced following liver injury. Mol Cell Biol 2000, 20:3742-3751.
31. Vanhara P, Hampl A, Kozubik A, Soucek K: Growth/ differentiation factor-15: prostate cancer suppressor or promoter [quest]. Prostate Cancer Prostatic Dis 2012, 15:320-328.
32. Martin Boegemann FJW: GDF15 and Hepcidin as Prognostic Factors in Patients with Prostate Cancer. J Mol Biomark Diagn 2014, 5:199. doi:10.4172/2155-9929.1000199
33. Liu X, Chi X, Gong Q, Gao L, Niu Y, Chi X, Cheng M, Si Y, Wang M, Zhong J, Niu J, Yang W: Association of Serum Level of Growth Differentiation Factor 15 with Liver Cirrhosis and Hepatocellular Carcinoma. PLOS ONE 2015, 10:e0127518.
34. Levi M, Keller TT, van Gorp E, ten Cate H: Infection and inflammation and the coagulation system. Cardiovasc Res 2003, 60:26-39.
35. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996, 88:881-886.
36. Schulz-Knappe P, Mägert HJ, Dewald B, Meyer M, Cetin Y, Kubbies M, Tomeczkowski J, Kirchhoff K, Raida M, Adermann K, others: HCC-1, a novel chemokine from human plasma. J Exp Med 1996, 183:295-299.
37. Wynn TA, Hesse M, Sandler NG, Kaviratne M, Hoffmann KF, Chiaramonte MG, Reiman R, Cheever AW, Sypek JP, Mentink-Kane MM: P-selectin suppresses hepatic inflammation and fibrosis in mice by regulating interferon ? and the IL-13 decoy receptor. Hepatology 2004, 39:676-687.
38. Soejima K, Mimura N, Hiroshima M, Maeda H, Hamamoto T, Nakagaki T, Nozaki C: A Novel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly, the von Willebrand Factor-Cleaving Protease? J Biochem (Tokyo) 2001, 130:475-480.
39. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Réti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM: ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008, 93:232-239.
40. Mukae H, ASHITANI J, Tokojima M, Ihi T, Kohno S, Matsukura S: Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology 2003, 8:326-331.
41. Kiryushko D, Korshunova I, Berezin V, Bock E: Neural cell adhesion molecule induces intracellular signaling via multiple mechanisms of Ca2+ homeostasis. Mol Biol Cell 2006, 17:2278-2286.
42. Campodónico PB, de Kier Joffé EDB, Urtreger AJ, Lauria LS, Lastiri JM, Puricelli LI, Todaro LB: The neural cell adhesion molecule is involved in the metastatic capacity in a murine model of lung cancer. Mol Carcinog 2010, 49:386-97.
43. Ugarte-Gil CA, Elkington P, Gilman RH, Coronel J, Tezera LB, Bernabe-Ortiz A, Gotuzzo E, Friedland JS, Moore DAJ: Induced Sputum MMP-1,-3 &-8 Concentrations during Treatment of Tuberculosis. PLoS ONE 2013, 8:e61333.
44. Martins C, Gama AC de C, Valcarenghi D, Batschauer AP de B: Markers of acute-phase response in the treatment of pulmonary tuberculosis. J Bras Patol E Med Lab 2014, 50:428-433.
45. Hong JY, Lee HJ, Kim SY, Chung KS, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Cho S-N, Kang YA: Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment. J Infect 2014, 68:252-258.
46. Corstjens PLAM, Tjon Kon Fat EM, de Dood CJ, van der Ploeg-van Schip JJ, Franken KLMC, Chegou NN, Sutherland JS, Howe R, Mihret A, Kassa D, van der Vyver M, Sheehama J, Simukonda F, Mayanja-Kizza H, Ottenhoff THM, Walzl G, Geluk A: Multi-center evaluation of a userfriendly lateral flow assay to determine IP-10 and CCL4 levels in blood of TB and non-TB cases in Africa. Clin Biochem 2016, 49:22-31.